Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting

References

• McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis 2006;12:409–15.
   PubMed Web of Science ®Google Scholar
• Pepin J, Valiquette L, Alary ME, Villemure P, Pelletier A, Forget K, . Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466–72.
   PubMed Web of Science ®Google Scholar
• Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999–2004. Emerg Infect Dis 2007;13:1417–9.
   PubMed Web of Science ®Google Scholar
• Teasley DG, Gerding DN, Olson MM, Peterson LR, Gebhard RL, Schwartz MJ, . Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983;2: 1043–6.
   PubMed Web of Science ®Google Scholar
• Barbut F, Decre D, Burghoffer B, Lesage D, Delisle F, Lalande V, . Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 1999; 43:2607–11.
   PubMed Web of Science ®Google Scholar
• Peláez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002;46:1647–50.
   PubMed Web of Science ®Google Scholar
• Musher DM, Aslam S, Logan N, Nallacheru S, Bhaila I, Borchert F, . Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005;40:1586–90.
   PubMed Web of Science ®Google Scholar
• Pepin J, Alary ME, Valiquette L, Raiche E, Ruel J, Fulop K, . Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:1591–7.
   PubMed Web of Science ®Google Scholar
• Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, . Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431–55.
   PubMed Web of Science ®Google Scholar
• Kazakova SV, Ware K, Baughman B, Bilukha O, Paradis A, Sears S, . A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006;166:2518–24.
   PubMedGoogle Scholar
• Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, . A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442–9.
   PubMed Web of Science ®Google Scholar
• Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, . A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005; 26:273–80.
   PubMed Web of Science ®Google Scholar
• Fedorko DP, Williams EC. Use of cycloserine–cefoxitin–fructose agar and l-proline-aminopeptidase (PRO Discs) in the rapid identification of Clostridium difficile. J Clin Microbiol 1997;35:1258–9.
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing of anaerobic bacteria. 7th ed. Wayne, PA: CLSI; 2007.
   Google Scholar
• Spigaglia P, Mastrantonio P. Evaluation of repetitive element sequence-based PCR as a molecular typing method for Clostridium difficile. J Clin Microbiol 2003;41:2454–7.
   PubMedGoogle Scholar
• Peláez T, Cercenado E, Alcala L, Marin M, Martin-Lopez A, Martinez-Alarcon J, . Metronidazole resistance in Clostridium difficile is heterogeneous. J Clin Microbiol 2008;46:3028–32.
   PubMed Web of Science ®Google Scholar
• Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, . Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010;50:194–201.
   PubMed Web of Science ®Google Scholar
• Hecht DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51:2716–9.
   PubMed Web of Science ®Google Scholar
• Sanchez JL, Johnson S, Gerding DN. Metronidazole susceptibility in Clostridium difficile isolates recovered from cases of C. difficile-associated disease treatment failures and successes. Anaerobe 1999;5:201–4.
   Google Scholar
• McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, . An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433–41.
   PubMed Web of Science ®Google Scholar
• Johnson S, Gerding DN. Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:1027–34.
   PubMed Web of Science ®Google Scholar
• Pepin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006;42:758–64.
   PubMed Web of Science ®Google Scholar
• Kenneally C, Rosini JM, Skrupky LP, Doherty JA, Hollands JM, Martinez E, . Analysis of 30-day mortality for Clostridium difficile-associated disease in the ICU setting. Chest 2007;132:418–24.
   PubMed Web of Science ®Google Scholar
• McGowan AP, Lalayiannis LC, Sarma JB, Marshall B, Martin KE, Welfare MR. Thirty-day mortality of Clostridium difficile infection in a UK National Health Service Foundation Trust between 2002 and 2008. J Hosp Infect. 2011; 77:11–15.
   PubMedGoogle Scholar
• Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, . Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254–60.
   PubMed Web of Science ®Google Scholar
• Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007;45:302–7.
   PubMed Web of Science ®Google Scholar
• Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, . Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011;364:422–31.
   PubMed Web of Science ®Google Scholar
• Aspevall O, Lundberg A, Burman LG, Akerlund T, Svenungsson B. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob Agents Chemother 2006;50: 1890–2.
   PubMed Web of Science ®Google Scholar
• Poilane I, Cruaud P, Torlotin JC, Collignon A. Comparison of the E test to the reference agar dilution method for antibiotic susceptibility testing of Clostridium difficile. Clin Microbiol Infect 2000;6:155–6.
   PubMedGoogle Scholar
• Killgore G, Thompson A, Johnson S, Brazier J, Kuijper E, Pepin J, . Comparison of 7 techniques for typing international epidemic strains of Clostridium difficile: restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J Clin Microbiol 2008;46:431–7.
   PubMed Web of Science ®Google Scholar